• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pear Therapeutics inks multiple agreements to expand digital therapeutic platform

April 6, 2021 By Sean Whooley

Pear TherapeuticsPear Therapeutics announced today that it entered into multiple agreements to bolster its prescription digital therapeutics (PDT) platform.

Boston-based Pear Therapeutics’ agreements are set to add to its library of digital biomarkers, machine learning algorithms, sensor-based technologies and digital therapeutics, according to a news release.

The agreements have been struck with technology companies including Empatica, etectRx and KeyWise as Pear Therapeutics seeks to build a comprehensive product offering for remote sensing, real-time personalization of digital therapeutic content and pharmaceutical dosing and overall enhanced patient outcomes.

Empatica develops medical wearables and digital biomarkers. The agreement will allow Pear to explore using the sensors to evaluate withdrawal symptoms in patients with substance use disorder, opioid use disorder and alcohol use disorder.

The agreement with etectRx will explore the development of digital therapeutics combined with digital pills, using etectRx’s FDA-cleared ID-Cap digital pill system. ID-Cap is an ingestible event marker designed to guide digital, patient-centric and value-based therapeutic interventions.

Finally, the deal with KeyWise is set to help Pear build capabilities to track and produce individualized mental health metrics with natural language processing PDTs through an artificial intelligence-enabled keystroke detection algorithm developed by KeyWise and licensed by Pear.

“We are excited to announce these agreements, which expand the leading PDT platform and create optionality as the space grows beyond neurobehavioral therapies,” Pear president & CEO Dr. Corey McCann said in the release. “Accessing external technologies allows us to build PDTs with new capabilities and continue to broaden their scope and effectiveness. With the ability to collect and quantify information in real-world settings and to potentially personalize products in real-time, PDTs present the opportunity to truly revolutionize healthcare.”

Filed Under: Business/Financial News, Contract Services, Drug-Device Combinations, Featured, Neurological, Patient Monitoring, Pharmaceuticals Tagged With: Empatica, etectrx, KeyWise, peartherapeutics

IN CASE YOU MISSED IT

  • Another BD Alaris infusion pump recall is Class I
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
  • Horizon touts data from trials for thyroid eye disease infusion treatment
  • Genentech touts study results for spinal muscular atrophy drug in babies

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS